

Thomas Strecker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6155833/publications.pdf>

Version: 2024-02-01

61
papers

3,651
citations

147801
31
h-index

133252
59
g-index

62
all docs

62
docs citations

62
times ranked

4370
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New England Journal of Medicine, 2016, 374, 1647-1660.	27.0	355
2	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	27.0	295
3	Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature, 2015, 524, 97-101.	27.8	272
4	Lassa Virus Z Protein Is a Matrix Protein Sufficient for the Release of Virus-Like Particles. Journal of Virology, 2003, 77, 10700-10705.	3.4	211
5	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	27.8	170
6	Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics. Science Translational Medicine, 2013, 5, 185ra68.	12.4	164
7	Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Reports, 2003, 4, 1084-1088.	4.5	136
8	Effect of Artesunate–Amodiaquine on Mortality Related to Ebola Virus Disease. New England Journal of Medicine, 2016, 374, 23-32.	27.0	111
9	Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. PLoS Pathogens, 2016, 12, e1005418.	4.7	105
10	Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clinical Infectious Diseases, 2017, 65, 855-859.	5.8	101
11	Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length. FEBS Letters, 2003, 538, 203-206.	2.8	97
12	Structure of the Lassa virus glycan shield provides a model for immunological resistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7320-7325.	7.1	95
13	Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Reports, 2003, 4, 1084-1088.	4.5	92
14	Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). Virus Research, 2004, 100, 249-255.	2.2	90
15	New Lineage of Lassa Virus, Togo, 2016. Emerging Infectious Diseases, 2018, 24, 599-602.	4.3	79
16	The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virology Journal, 2006, 3, 93.	3.4	78
17	The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C. Virology Journal, 2006, 3, 41.	3.4	64
18	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine, 2017, 19, 107-118.	6.1	64

#	ARTICLE	IF	CITATIONS
19	Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. <i>Virology</i> , 2004, 321, 134-143.	2.4	60
20	Efficient Budding of the Tacaribe Virus Matrix Protein Z Requires the Nucleoprotein. <i>Journal of Virology</i> , 2010, 84, 3603-3611.	3.4	59
21	Multifunctional Nature of the Arenavirus RING Finger Protein Z. <i>Viruses</i> , 2012, 4, 2973-3011.	3.3	58
22	Safety and immunogenicity of rVSVÎ”G-ZEBOV-GP Ebola vaccine in adults and children in LambarÃ©nÃ©, Gabon: A phase I randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002402.	8.4	57
23	Viral Protein Determinants of Lassa Virus Entry and Release from Polarized Epithelial Cells. <i>Journal of Virology</i> , 2010, 84, 3178-3188.	3.4	56
24	Interaction with Tsg101 Is Necessary for the Efficient Transport and Release of Nucleocapsids in Marburg Virus-Infected Cells. <i>PLoS Pathogens</i> , 2014, 10, e1004463.	4.7	46
25	Sangassou Virus, the First Hantavirus Isolate from Africa, Displays Genetic and Functional Properties Distinct from Those of Other Murinae-Associated Hantaviruses. <i>Journal of Virology</i> , 2012, 86, 3819-3827.	3.4	44
26	Characterization of Lassa Virus Glycoprotein Oligomerization and Influence of Cholesterol on Virus Replication. <i>Journal of Virology</i> , 2010, 84, 983-992.	3.4	41
27	Vacuolar Protein Sorting Pathway Contributes to the Release of Marburg Virus. <i>Journal of Virology</i> , 2009, 83, 2327-2337.	3.4	39
28	Comprehensive characterization of cellular immune responses following Ebola virus infection. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw508.	4.0	38
29	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 572-582.	4.0	38
30	Role of the Transmembrane Domain of Marburg Virus Surface Protein GP in Assembly of the Viral Envelope. <i>Journal of Virology</i> , 2007, 81, 3942-3948.	3.4	37
31	Analysis of Diagnostic Findings From the European Mobile Laboratory in GuÃ©ckÃ©dou, Guinea, March 2014 Through March 2015. <i>Journal of Infectious Diseases</i> , 2016, 214, S250-S257.	4.0	32
32	Lassa Virus Glycoprotein Signal Peptide Displays a Novel Topology with an Extended Endoplasmic Reticulum Luminal Region. <i>Journal of Biological Chemistry</i> , 2004, 279, 12293-12299.	3.4	30
33	IRF9 Prevents CD8 ⁺ T Cell Exhaustion in an Extrinsic Manner during Acute Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	30
34	Inhibition of Lassa Virus Glycoprotein Cleavage and Multicycle Replication by Site 1 Protease-Adapted Î±1-Antitrypsin Variants. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e446.	3.0	29
35	Detectable Vesicular Stomatitis Virus (VSV)â€”Specific Humoral and Cellular Immune Responses Following VSVâ€”Ebola Virus Vaccination in Humans. <i>Journal of Infectious Diseases</i> , 2019, 219, 556-561.	4.0	29
36	Field Evaluation of Capillary Blood Samples as a Collection Specimen for the Rapid Diagnosis of Ebola Virus Infection During an Outbreak Emergency. <i>Clinical Infectious Diseases</i> , 2015, 61, 669-675.	5.8	28

#	ARTICLE	IF	CITATIONS
37	Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea. <i>Scientific Reports</i> , 2016, 6, 21977.	3.3	28
38	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 507-516.	9.1	26
39	Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1124-1133.	4.0	24
40	Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. <i>Npj Vaccines</i> , 2020, 5, 71.	6.0	21
41	Serological Evidence for the Circulation of Ebolaviruses in Pigs From Sierra Leone. <i>Journal of Infectious Diseases</i> , 2018, 218, S305-S311.	4.0	20
42	Evidence for a decrease in transmission of Ebola virus–Lofa County, Liberia, June 8–November 1, 2014. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 1067-71.	15.1	20
43	Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail. <i>FEBS Letters</i> , 2010, 584, 4379-4382.	2.8	19
44	Early transmission and case fatality of Ebola virus at the index site of the 2013–16 west African Ebola outbreak: a cross-sectional seroprevalence survey. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 429-438.	9.1	19
45	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020, 71, 2872-2879.	5.8	17
46	Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany. <i>Genome Announcements</i> , 2016, 4, .	0.8	15
47	Humoral and cellular immune response induced by rVSV ^{GP} -ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea. <i>Vaccine</i> , 2020, 38, 4877-4884.	3.8	14
48	The microtubule motor protein KIF13A is involved in intracellular trafficking of the Lassa virus matrix protein Z. <i>Cellular Microbiology</i> , 2013, 15, 315-334.	2.1	12
49	Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. <i>Scientific Reports</i> , 2020, 10, 14289.	3.3	12
50	The New World arenavirus Tacaribe virus induces caspase-dependent apoptosis in infected cells. <i>Journal of General Virology</i> , 2016, 97, 855-866.	2.9	12
51	Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 724-732.	3.0	9
52	Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis. <i>Frontiers in Immunology</i> , 2022, 13, 857481.	4.8	9
53	Distinct Molecular Mechanisms of Host Immune Response Modulation by Arenavirus NP and Z Proteins. <i>Viruses</i> , 2020, 12, 784.	3.3	8
54	Determining Ancestry between Rodent- and Human-Derived Virus Sequences in Endemic Foci: Towards a More Integral Molecular Epidemiology of Lassa Fever within West Africa. <i>Biology</i> , 2020, 9, 26.	2.8	8

#	ARTICLE	IF	CITATIONS
55	Variability of interferon- λ induction and antiviral activity in Nipah virus infected differentiated human bronchial epithelial cells of two human donors. Journal of General Virology, 2017, 98, 2447-2453.	2.9	7
56	Polymer microarrays rapidly identify competitive adsorbents of virus-like particles. Biointerphases, 2020, 15, 061005.	1.6	5
57	Proteomic landscape of SARS-CoV-2 and MERS-CoV infected primary human renal epithelial cells. Life Science Alliance, 2022, 5, e202201371.	2.8	5
58	Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1275-1279.	2.3	3
59	Determining the effect of different environmental conditions on Ebola virus viability in clinically relevant specimens. Emerging Microbes and Infections, 2018, 7, 1-7.	6.5	3
60	CP100356 Hydrochloride, a P-Glycoprotein Inhibitor, Inhibits Lassa Virus Entry: Implication of a Candidate Pan-Mammarenavirus Entry Inhibitor. Viruses, 2021, 13, 1763.	3.3	2
61	Ebola Virus Neutralizing Antibodies in Dogs from Sierra Leone, 2017. Emerging Infectious Diseases, 2020, 26, 760-763.	4.3	1